Psilocybin reshapes cortical inhibition through selective interneuron recruitment.
Pasha A. Davoudian, Quan Jiang, Cory A. Knox, Neil K. Savalia, Ling-Xiao Shao, Joshua Wilson, Amanda M. Weiner, Catherine W. Chong, Clara Liao, Jack D. Nothnagel, Takeshi Sakurai, Alex C. Kwan
bioRxiv : the preprint server for biology April 17, 2026 preprint DOI: 10.64898/2026.04.16.718963 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study |
|---|---|
| Population | Mice |
| Intervention | Psilocybin |
| Topics | Depression Psilocybin |
| Keywords | Gabaergic neurons Disinhibition Microcircuit Psychedelic Serotonin receptor |
| Key findings | Psilocybin reduces firing of somatostatin-expressing interneurons and increases activity of parvalbumin-expressing interneurons in the mouse medial frontal cortex via the 5-HT1A receptor. |
Abstract
Psychedelics show therapeutic potential for treating psychiatric disorders. While studies have emphasized the roles of cortical pyramidal cells, GABAergic neurons also express serotonin receptors and are therefore likely targets of psychedelics. In this study, we determine the effect of psilocybin on the activity dynamics of major GABAergic cell types in the mouse medial frontal cortex. Psilocybin reduces the firing of somatostatin-expressing interneurons, but increases the activity of parvalbumin-expressing interneurons. This cell type-specific response is unlikely to involve vasoactive intestinal peptide-expressing interneurons. Instead, pharmacological blockade and conditional knockout experiments demonstrate that psilocybin acts on the 5-HT1A receptor at SST interneurons, which contributes to the drug's long-term behavioral effects. Collectively, the results reveal that the classic psychedelic psilocybin alters cortical inhibition in a cell type-specific manner.